MREO $1.33 91 million shares today we could see a bid war coming next week.
AstraZeneca
$AZN
today + 1.68% is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma
$MREO
, today + 62.46%, The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist's partners, which include Novartis